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Abstract
Human apolipoprotein E (apoE) exists in three isoforms: apoE2, apoE3 and apoE4. APOE ε4 (E4)
is a major genetic risk factor for cardiovascular disease (CVD) and Alzheimer's disease (AD).
ApoE mediates cholesterol metabolism by binding various receptors. The low-density lipoprotein
receptor (LDLR) has a high affinity for apoE, and is the only member of its receptor family to
demonstrate an apoE isoform specific binding affinity (E4>E3>>E2). Evidence suggests that a
functional interaction between apoE and LDLR influences the risk of CVD and AD. We
hypothesize that the differential cognitive effects of the apoE isoforms are a direct result of their
varying interactions with LDLR. To test this hypothesis, we have employed transgenic mice that
express human apoE2, apoE3, or apoE4, and either human LDLR (hLDLR) or no LDLR (LDLR−/
−). Our results show that plasma and brain apoE levels, cortical cholesterol, and spatial memory
are all regulated by isoform-dependent interactions between apoE and LDLR. Conversely, both
anxiety-like behavior and cued associative memory are strongly influenced by APOE genotype,
but these processes appear to occur via an LDLR-independent mechanism. Both the lack of LDLR
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and the interaction between E4 and the LDLR were associated with significant impairments in the
retention of long term spatial memory. Finally, levels of hippocampal apoE correlate with long
term spatial memory retention in mice with human LDLR. In summary, we demonstrate that the
apoE-LDLR interaction affects regional brain apoE levels, brain cholesterol, and cognitive
function in an apoE isoform-dependent manner.
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LDLR; Alzheimer's
Introduction
Abnormalities in lipid metabolism are strongly linked to several diseases such as
cardiovascular disease (CVD) and Alzheimer's disease (AD) (Yusuf et al., 2004, Gamba et
al., 2012). Efficient cholesterol transport is an important part of the cellular remodeling that
underlies synaptic plasticity and breakdown of this process has been proposed to contribute
to dementia (Gamba et al., 2012, Martin et al., 2010). Two essential regulatory components
of cholesterol metabolism are apolipoprotein E (apoE) and the low density lipoprotein
receptor (LDLR).
ApoE is an essential component of lipoprotein particles in both the brain and periphery, and
exists in three isoforms in the human population: APOε*2 (E2), APOε*3 (E3), and APOε*4
(E4) (Raber et al., 2004, Mahley and Rall, 2000). While the isoforms only differ from one
another by one or two amino acids, they show dramatic differences in structure, function and
disease-associated risk. For instance, E4 is associated with an increased risk of CVD
(Mahley and Rall, 2000) and AD (Raber et al., 2004). ApoE is a primary component of
various lipoprotein particles, and binds to a variety of cell surface receptors (Hauser et al.,
2011). One such receptor is LDLR, a trans-membrane receptor expressed in the liver, brain
and other tissues (Jeon and Blacklow., 2005). ApoE and LDLR play critical roles in the
regulation of cholesterol metabolism in the peripheral vasculature (Go and Mani, 2012) and
likely play a similarly critical role in the brain.
The apoE-LDLR interaction appears critical in both CVD and AD. For example, the
disparities in CVD risk usually associated with APOE genotype disappear in patients who
lack functioning LDLR, suggesting that the diseases-modifying effects of the apoE isoforms
depend on the presence of a fully functioning LDLR protein (Vermissen et al., 2011). In
mice, introduction of human LDLR results in higher plasma cholesterol and increased
cardiovascular complications in the presence of E4 (Altenburg et al., 2007, Malloy et al.,
2004, Johnson et al., 2013). This effect does not occur in mice expressing E3, and in the
presence of E2 actually lowers cholesterol and improves cardiovascular outcomes (Knouff et
al., 2001).
In the context of AD, the risk of disease is modified by various LDLR polymorphisms
(Gopalraj et al., 2005, Zou et al., 2008). Furthermore, the risk associated with a certain
LDLR polymorphism differs dramatically depending on the patients’ APOE genotype,
implying that a functional interaction between apoE and LDLR determines AD risk (Cheng
et al., 2004, Retz et al., 2001).
In contrast to cardiovascular function, it is unclear whether apoE isoform-dependent
interactions with human LDLR affect brain function. Therefore, in this study we employed a
humanized mouse model expressing both human apoE isoforms (targeted replacement) and
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human LDLR to study the effects of the apoE-LDLR interactions on brain function. We
demonstrate that the apoE-LDLR interaction affects regional brain apoE levels, brain
cholesterol, and cognitive function in an apoE isoform-dependent manner.
Methods
Experimental animals
Mice expressing human apoE isoforms under control of the mouse apoE promoter (targeted
replacement mice) (Sullivan et al., 1997, Sullivan et al., 1998, Knouff et al., 1999) were
crossed with mice deficient in LDLR (Ishibashi et al., 1993, Knouff et al., 2004) or with
mice hemizygous for a targeted replacement of the mouse LDLR gene with the stabilized
human LDLR minigene (Malloy et al., 2004, Knouff et al., 2001). All mice were
backcrossed for at least 6 generations to the C57BL/6 background prior to crossing them for
the experiments in the current study. LDLR deficient (LDLR−/−) and hemizygous human
LDLR (LDLRh/−) mice of similar APOE genotype were all littermates with a common
genetic background obtained from crossbreeding (example: E2/E2 LDLRh/− × E2/E2
LDLR−/−). The mice were fed normal chow diet ad libitum (5.3% fat and 0.02% cholesterol,
Prolab IsoPro RMH 3000; Agway Inc). All analyses were carried out at 10-12 months of age
(n = 6 to 12). Only female mice were used for the current study. All procedures complied
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and
with IACUC approval at Oregon Health & Sciences University.
Behavioral Analyses
Anxiety (Elevated Zero Maze, Day 1)—The elevated zero maze enclosure (Kinder
Scientific, Poway, CA) consisted of four sections (6 cm wide), alternating between open and
closed environments. Mice were placed into an open area of the maze and allowed to
explore for 10 minutes. An automated photobeam detection method (Kinder Scientific,
Poway, CA) was used to track mouse movements: distance moved (cm), time spent in the
open and closed areas (s) as well as crossings between environments.
Novel Object Recognition (Days 2-5)—Mice were placed into a brightly lit square
arena (40.6 × 40.6 cm) and habituated to the open field arena over two days, with a one 10-
minute trial per day. On the third day, mice were exposed to the arena containing two
identical objects (small orange hexagonal prisms) placed 15 cm from the adjacent walls and
10 cm apart for 15 minutes. On day five, one of the identical objects (“familiar”) was
replaced with a novel object (small green triangular prism) of identical dimensions.
Movement and exploration were tracked and analyzed with video software from Noldus
Information Technologies (Ethovision XT 7, Wageningen, The Netherlands). Clear visuo-
spatial orientation to the object, within 2 cm proximity, as well as interaction with the object
was coded as exploratory behavior, and the percent time spent exploring the novel versus
familiar object was calculated.
Spatial Learning and Memory in the Water Maze (Days 8-15)—The water maze
consisted of a circular pool (diameter 140 cm), filled with opaque water (white chalk added,
24°C) divided conceptually into four quadrants. Mice were first trained to locate an “escape”
platform (plexiglass circle, 6 cm radius) submerged 2 cm below the surface of the water, by
the use of a cue (a colored cylinder, 2.5 cm radius, 8 cm height) during the “Visible” trials
(days 8-9). Mice were given two sessions per day (separated by three hours) consisting of
two trials each (separated by 10 minutes). The location of the platform was moved for each
session between the four quadrants to avoid procedural biases in task learning. Subsequent
to the “Visible Platform” trials, mice were trained to locate the platform sans cue during the
“Hidden Platform” trails, which required the mice to rely on extra-maze cues for spatial
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reference and orientation. Extra-maze cues consisted of four large (50 × 50 cm) cues of
different shapes and color combinations, positioned at the borders of the four quadrants.
Cues were placed 100 cm from the ground, and 90 cm away from the edge of the pool. The
platform was not rotated during the Hidden Platform trials, remaining in the “Target”
quadrant. Spatial memory retention was assessed 24 hours following the conclusion of the
second and fourth sessions of “Hidden Platform” training, as well as 72 hours following the
final “Hidden Platform” training session. The submerged platform was removed and spatial
memory retention assessed during these “Probe” trials by analyzing the time spent
swimming in the target quadrant compared to the time spent in the three non-target
quadrants.
Associative Learning and Memory (Days 16-17)—In this task, mice learned to
associate a conditioned stimulus (CS, e.g. the environmental context, or a discrete cue -
tone) with a mild foot shock (unconditioned stimulus, US). Freezing, defined as
somatomotor immobility with the exception of respiration, is considered a post-exposure
fear response, and is a widely used indicator of conditioned fear (Maren 2001). Mice were
trained and tested using a Med Associates mouse fear conditioning system (PMED-VFC-
NIR-M, Med Associates, St. Albans, Vermont) utilizing Med Associates VideoFreeze
automated scoring system. Mice were placed inside a dark fear conditioning chamber, and
chamber lights were turned on at zero seconds, followed by a 160 second habituation period
and a subsequent 30-second (80 dB) tone (cue). A 2-second 0.35 mA foot shock was
administered at 188 seconds, co-terminating with the tone at 190 seconds. This series was
repeated for a total of four times. Twenty four hours later, contextual associative memory
was assessed during re-exposure to the training environment for 600 seconds. Three hours
later, mice were exposed to a modified environment (scented with vanilla extract, novel
floor texture covering the shock-grid, and rounded walls), allowed to habituate to it for 160
seconds, and they were then exposed to the sound cue for a second period of 30 seconds.
This series was repeated a total of five times. Motion during shock (proprietary index, Med
Associates) during the training day was measured to account for sensor-motor differences in
response to the aversive stimulus. Associative learning was measured as the percent time
spent freezing in response to the environment (contextual) or tone (cued).
Gene expression
mRNA was purified from mouse cortex using an Automated Nucleic Acid Workstation ABI
6700, and real-time PCR was performed using an ABI PRISM 7700 Sequence Detector
(Applied Biosystems). In order to compare to murine LDLR expression, a primer extension
assay was designed to quantify both human and mouse message simultaneously using a
primer 5′-GGA GCA CGT CTT GGG GGG ACA GCC T-3′ corresponding to a shared
sequence within exon 3 of the two LDLR genes. Primer extension was terminated by dd-
CTP, resulting in murine message extension by 5 bp and human message extension by 3 bp.
The 30- and 28-bp fragments were separated in a denaturing 20% polyacrylamide gel. A
primer 5′-GCA GCG AAC TTT ATT GAT GGT ATT 3′ was included in each reaction to
determine the expression of the glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for
normalization.
Biochemical analyses
Mice were administered a ketamine-xylazine-acepromazine cocktail intraperitoneally
(0.01ml/g of 25mg/ml ketamine (Sigma), 0.625mg/ml acepromazine (Vetus Animal Health),
3.125 mg/ml xylazine (Sigma)), and intracardially perfused with 20 ml of 0.9% Phosphate-
Buffered Saline. Brains were removed and the hippocampus, cortex, amygdale, and
cerebellum were manually dissected from the right hemisphere following an established
protocol (Spijker 2011). Dissected brain regions were immediately frozen in liquid nitrogen
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and stored at −80C until analysis. Regional brain tissues were homogenized in 500 μl of
RIPA buffer (1% NP-40, 0.1% SDS) (Sigma) containing protease inhibitor (Roche). Protein
expression by Western blot was determined using antibodies against human apoE
(Calbiochem, 1:2,500 dilution) and β-actin (1:5,000 dilution). ApoE levels were also
measured in plasma using a sandwich ELISA as previously described (Sullivan et al., 2011).
Briefly, plasma samples (diluted 3000-fold in PBS-T (1× PBS, pH 7.4, 0.05% tween-20) and
0.4% glycine) were loaded into a 96-well plate that had been coated with an anti-apoE
antibody (goat anti-human apoE; 1–2000 dilution; Millipore, San Francisco, CA, USA).
Following overnight incubation at 4 °C, the samples were removed and the plate washed 3
times with PBS-T prior to incubation with a biotinylated anti-apoE antibody (goat anti-
human apoE; 1:5000; Biodesign, Saco, ME, USA) for 1 h at room temperature. The plates
were then washed again 3 times with PBS-T and incubated with streptavidin-HRP for an
additional 1 h at room temperature. The immunocomplex was reacted with TMB substrate
and detected using a Spectra MAX 190 (Molecular Devices, Sunnyvale, CA, USA) plate
reader. Levels of apoE were normalized to a standard curve generated using recombinant
human apoE (Biodesign, Saco, ME, USA). Plasma apoE levels were determined in triplicate
and expressed as the amount of apoE per milliliter.
Cholesterol measurements
Blood was collected retro-orbitally under anesthesia (isofluorane). Approximately 100 μl of
whole blood was collected into a tube containing 5 μl of 0.5M EDTA. Blood was
centrifuged at 5,500 rpm for 10 min and plasma was removed and stored at −80 °C until
analysis. Plasma cholesterol was measured using a colorometric assay (Wako) according to
manufacturer's instructions. For brain cholesterol analyses, lipids were extracted from cortex
and hippocampus homogenates by chloroform:methanol (2:1) extraction. Internal standards
were added and the samples were dried and saponified with alcoholic KOH and extracted
into hexane. Samples were derivatized with N,O-Bis(trimethylsilyl)trifluoroacetamide
(BSTFA) (Thermo-Scientific Rockford, IL) and cholesterol concentration was measured by
capillary column gas chromatography on an Agilent (Santa Clara, CA) gas chromatograph
(Model 6890N) with a ZB1701 column (30 m, 0.25 mm ID, 0.25 μm film; Phenomenex,
Torrance, CA) and a FID detector. An internal standard (epicoprostanol; Sigma, St. Louis,
MO) and an authentic cholesterol standard (Steraloids, Newport, RI) were used for
calibration.
Statistical analyses
Data are expressed as mean ± standard error. Multiple groups and/or multiple time points
were analyzed using multivariate ANOVA or repeated measures ANOVA, using SPSS
software (Chicago, IL). To assess potential correlations between apoE and performance in
the spatial memory test, two-tailed Pearson correlation calculations were analyzed using
GraphPad Prism software (San Diego, CA).
Results
Physical characteristics and motor function
No significant differences were observed in body weight, or in adipose tissue, liver, or brain
weight (Table 1). There were also no apparent differences in health or physical appearance,
and all groups performed similarly with regard to activity levels in an open field,
sensorimotor function on a Rotarod, and swim speeds in the water maze (Table 2).
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Novel object recognition is unaffected by APOE and LDLR genotype
The Novel object recognition task is based on rodents’ natural curiosity and propensity to
orient their head toward a novel stimulus (Honey et al., 1998). On the first day of this
paradigm, mice were allowed 15 minutes to explore an open arena containing two identical
(“Familiar”) objects. All groups spent a comparable amount of time exploring each of the
two identical objects (Figure 1A). When exposed to a Novel object 24 hours later, all
experimental groups – regardless of APOE or LDLR genotype – spent significantly more
time examining the novel object, demonstrating robust object recognition memory (Figure
1B).
ApoE4 is associated with increased anxiety, independent of LDLR
APOE genotype has been shown to modulate anxiety and anxiety-like behavior in humans
and in mice (Raber et al., 2007). To test whether apoE isoform effects on measures of
anxiety are dependent on the LDLR, we used the elevated zero maze, a canonical test of
anxiety-like behavior (Shepard et al., 1994). There was a significant effect of APOE
genotype on numbers of entries into open areas (p < 0.01, ANOVA) as well as total time
spent in the open areas (p < 0.001 respectively by ANOVA) of elevated zero maze (Figure
2A-B). Mice with E4 displayed more anxiety-like behavior than those with E3 or E2. In both
the absence and presence of human LDLR, mice with E4 spent less time in the open area of
the zero maze (13.0 ± 3.6, 14.3 ± 4.2%) compared to mice with E3 (18.6 ± 6.0, 19.4 ± 6.1
%) or E2 (24.5 ± 4.5, 26.3 ± 8.9 %) (Figure 2B). This data suggests that the apoE isoforms
differentially affect anxiety-like behavior (E4 > E3 ≥ E2) through an LDLR-independent
process.
Contextual associative memory is unaffected by APOE or LDLR but cued associative
memory is regulated by APOE
To determine the role of the apoE-LDLR interactions in associative learning and memory,
we employed two distinct testing conditions to assess contextual and cued fear conditioning
(Figure 3A). First, mice were trained to associate a conditioned stimulus, i.e. a tone, with a
mild foot shock (unconditioned stimulus), and thereby come to fear the conditioned
stimulus. Trained mice displayed this conditioned fear by freezing – ceasing all movement
except for respiration (Maren et al., 2001). There were no group differences in the response
to the shock (Figure 3B). All groups demonstrated an increase in freezing across the training
session (p < 0.01, repeated measures), indicating a learned fear response (Figure 3-C-D).
Freezing response during training was not affected by APOE or LDLR and there was no
APOE × LDLR interaction, although there was a trend towards higher freezing in mice with
E4 (APOE effect p = 0.079, repeated measures).
To test contextual memory, mice were exposed to an identical environment as that
encountered during their training. There was no difference in contextual freezing between
any of the experimental groups (Figure 3E).
To test cued memory, a Pavlovian-type response heavily regulated by the amygdala, mice
were placed in a novel environment (unique compartment shape, floor texture and scent) and
exposed to the tone. While LDLR did not alter the cued fear conditioning response and there
was no APOE × LDLR interaction, there was a significant effect of APOE (p < 0.01,
repeated measures) on freezing in response to the tone. In LDLR−/− mice, the freezing
response to the tone was apoE isoform-dependent (E4 > E3 > E2). LDLR−/− mice with E4
had a significantly higher freezing response compared to mice with E3 (p < 0.05) or E2 (p <
0.01), while mice with E3 tended to freeze more than mice with E2 (p = 0.063) (Figure 3F).
In the presence of human LDLR, mice with E3 or E4 had a similar freezing response to the
tone, while mice with E2 had significantly lower freezing levels (p < 0.05, repeated
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measures) compared to mice with E4, and there was a trend towards lower freezing levels
than in mice with E3 (p = 0.084) (Figure 3G). In summary, there was no effect of APOE,
LDLR or APOE*LDLR interaction for contextual fear conditioning, but a strong effect of
APOE for cued fear conditioning (E4 > E3 > E2) that was independent of LDLR status.
Spatial memory is impaired in the absence of LDLR and in mice with apoE4 and human
LDLR
The Morris water maze is a well-established test to identify spatial learning and/or memory
deficits and has been employed in numerous studies of mouse models of neurological
disease (Vorhees and Williams, 2006). There were no group differences in swim speeds
(Table 2). Therefore, time to reach the platform (latency) was used as performance measure.
There were no group differences in ability to reach the platform during the visible platform
sessions (Figure 4A-B, “Visible”). Performance improved during the visible and hidden
platform sessions (Session effect in each, p < 0.01). These data indicate that there were no
genotype differences in cued task learning or spatial learning.
None of the groups showed spatial memory retention in the first probe trial (not shown).
However, following additional training, some groups did show spatial memory retention. In
the second probe trial (P2), LDLR deficient mice failed to show a preference for the target
quadrant, regardless of APOE genotype (Figure 4C) and the majority of LDLR−/− mice
displayed un-directed search patterns (Figure 4G, top row). However, the presence of human
LDLR resulted in significant preference for the target quadrant and clear search strategies in
E2, E3 and E4 mice (47.0 ± 25.8, 41.5 ± 12.2, and 50.0 ± 21.6 % time in target quadrant,
respectively) (Figure 4D, H top row).
To assess long-term memory retention, we performed a more challenging probe trial 72
hours following the final “Hidden Platform” session. As in the first two probe trials, mice
lacking the LDLR failed to show a preference for the target quadrant, regardless of APOE
genotype (Figure 4E, G bottom row). Conversely, E2 and E3 mice with human LDLR
showed a clear preference for the target quadrant (42.4 ± 18.1 and 40.7 ± 12.5 % time in
target quadrant, respectively) (Figure 4F), and accurate, focused search strategies (Figure
4H, bottom row, shows representative trials). In contrast, E4 mice with human LDLR did
not spend significantly more time in the target quadrant than the right and opposite
quadrants, suggesting deficiencies in spatial memory. Taken together, both the absence of
LDLR (regardless of apoE isoform), as well as the specific combination of E4 and human
LDLR, result in deficits in long-term spatial memory.
Plasma Cholesterol is altered by APOE*LDLR interaction
Fasting plasma cholesterol concentrations were drastically altered by both APOE and LDLR
genotype (APOE effect p < 0.001, LDLR effect p < 0.001, APOE × LDLR interaction, p <
0.001, ANOVA). Human LDLR expression considerably lowered total plasma cholesterol
regardless of apoE isoforms (Table 1). Plasma cholesterol was higher in mice with E2
compared to mice with E3, whether or not human LDLR was expressed. However, while
plasma cholesterol tended to be lower in E4 mice compared to E3 mice when there was no
LDLR, introduction of the human LDLR resulted in significantly higher plasma cholesterol
in E4 mice compared to E3 mice (Table 1).
To determine whether the apoE-LDLR interaction influences brain cholesterol content, we
performed GC/MS analyses of cholesterol concentrations in the cortex and hippocampus of
mice with human LDLR. Hippocampal cholesterol was not affected by APOE genotype
(Figure 5, shaded bars). Cholesterol levels in the cortex did not significantly differ by APOE
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genotype. However, there was a trend towards lower cholesterol in human LDLR mice with
E4 compared to human LDLR mice with E3 or E2 .
Brain apoE levels are regulated by APOE*LDLR interaction; decreased in mice with apoE4
and human LDLR
In mice with human LDLR, expression of LDLR in the brain was within a physiological
range comparable to that of WT mice, ranging between 30.3 to 145.8% of wild type mice
(WT). There was no significant difference in human LDLR expression between E2, E3 and
E4 mice (88.5 ± 17.2, 92.1 ± 10.7, and 87.3 ± 19.6 % of WT, respectively) (Figure 6A).
To determine the regulatory effects of human LDLR expression on the various apoE
isoforms, we performed western blot analyses of plasma and regional brain apoE
concentrations. Plasma apoE levels were modulated by APOE genotype as well as markedly
lowered by LDLR expression (LDLR effect p < 0.001, APOE effect p < 0.01 by ANOVA).
In the absence of LDLR, plasma apoE concentrations did not differ by APOE genotype
(Figure 6B, left). However, when human LDLR was present, plasma apoE concentrations
were significantly higher in mice with E2 (20.3 ± 1.5 μg/ml) than E3 or E4 (7.0 ± 0.9 and
5.9 ± 0.5 μg/ml, respectively) (Figure 6B-C).
In the brain, there was a significant effect of APOE, LDLR and a significant APOE × LDLR
interaction when all regions were analyzed together (p < 0.01, repeated measures). In most
brain regions examined, APOE genotype had no effect on levels of apoE in the absence of
LDLR. LDLR deficient mice with E2, E3 or E4 had similar levels of apoE in the cortex,
hippocampus and amygdala (Figure 6E-G, left side). However, in the cerebellum of
LDLR−/− mice, levels of apoE were significantly greater in E2 than E3 or E4 mice (Figure
6D-H, left side).
In contrast, a clear pattern (E2 > E3 > E4) emerged in all brain regions measured in mice
with human LDLR (APOE*LDLR effect, all regions p < 0.01). In human LDLR mice, apoE
levels in the hippocampus and amygdala were higher in E2 than E4 mice, and apoE levels in
cortex and cerebellum were higher in E2 than in either E3 or E4 (Figure 6E-H, right side).
Together, these data suggest that the LDLR regulates brain apoE levels in an isoform-
dependent manner, and that regional variations in apoE level may also exist.
Based on these findings, we inquired how levels of apoE differed in the presence of human
LDLR compared to mouse LDLR, as the human apoE Targeted Replacement (TR) mice are
a commonly used model in the AD and CVD fields. For comparison, western blot analysis
of plasma and regional brain apoE were performed in parallel for E2, E3 and E4 mice with
the endogenous mouse LDLR. Similar to previously published reports (Riddell et al., 2008,
Sullivan et al., 2011), we observed significantly elevated plasma apoE levels in TR mice
with human E2 compared to those with E3 and E4 (p<0.01), as well as a significant
genotype effect on apoE levels when all regions were analyzed together (p<0.01, Repeated
Measures) as well as in the cortex (p < 0.05, ANOVA) (Supplemental Figure 1).
Hippocampus apoE correlates with long-term spatial memory retention
Spatial memory retention was impaired in mice lacking LDLR when tested at both 24 and
72 hours post-training, regardless of APOE genotype. When human LDLR was introduced,
mice with E2 and E3 demonstrated robust spatial memory retention at both 24 and 72 hours.
While mice with human LDLR and E4 performed similar to their E2 and E3 counterparts in
the 24 hour spatial memory test, they showed impaired long term memory retention during
the 72 hour test. Based on this genotype difference, we next analyzed the relationship
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between long term memory retention and apoE levels in the hippocampus – a brain region
critical for performance on this task.
In mice with human LDLR, better performance in the 72 hour probe trial of the water maze
was associated with higher levels of hippocampal apoE (Figure 7B). Hippocampal apoE
levels were positively correlated with the percent time spent in the target quadrant in the
probe trial in human LDLR mice with E2 (r2 = 0.695, p < 0.05, Pearson correlation) and E3
(r2 = 0.695, p < 0.05 and r2 = 0.884, p < 0.01, Pearson correlation). While the overall trend
was similar, the correlation did not reach significance in human LDLR mice with E4 (r2 =
0.468, p = 0.089, Pearson correlation). When the data of human LDLR mice with all three
apoE isoforms were analyzed together, there was a strong positive correlation between
hippocampal apoE levels and the percent time spent in the target quadrant (r2 = 0.722, p <
0.001, Pearson correlation). This positive correlation was not present in LDLR deficient
mice, irrespective of APOE genotype (all LDLR−/− groups combined, r2 = 0.0065, p =
0.7502, Pearson correlation) (Figure 7A). Additionally, no group showed a correlation
between water maze performance and apoE levels in the cortex, amygdale or cerebellum,
nor did apoE levels in any of these brain regions correlate with other behavioral tests (object
recognition, anxiety, fear conditioning, or spatial memory retention in the water maze probe
trials). These data suggest a role for the LDLR in regulating hippocampal apoE levels and
long-term retention of spatial memory.
Discussion
In this study, we examined whether the interaction between apoE and the LDLR results in
apoE isoform-dependent cognitive and biological effects. We show that both anxiety-like
behavior and cued associative memory are strongly influenced by APOE genotype in both
the absence and presence of human LDLR, suggesting that these processes occur via an
LDLR independent mechanism. Conversely, the interaction between apoE and LDLR
appears especially important in the regulation of plasma and brain apoE levels and spatial
memory retention in the water maze. Particularly, both the lack of LDLR and the specific
interaction between apoE4 and the LDLR were associated with impairments in the retention
of long-term spatial memory. Furthermore, in mice with human LDLR, hippocampal apoE
levels correlated with long-term spatial memory retention.
Together with epidemiological studies (Cheng et al., 2005, Gopalraj et al., 2005, Retz et al.,
2001, Vermissen et al., 2011, Zou et al., 2008), these data point toward a functional
interaction between apoE and LDLR as a potential mechanism to explain the apoE isoform-
dependent disease risks associated with both CVD and AD. While numerous lipoprotein
receptors have been shown to interact with apoE in the brain, the LDLR is the only receptor
in its class of receptors to show varying binding affinities for the three apoE isoforms (E4 >
E3 >> E2) (Innerarity et al., 1983, Yamamoto et al., 2008). Interestingly, the increased CVD
risk normally associated with APOE4 genotype disappears in Familial Hypercholesterolemia
(FH) patients, who lack functioning LDLR (Vermissen et al., 2011). While this may simply
be due to the effects of APOE4 being overwhelmed by severely elevated cholesterol levels
in FH patients, an alternative explanation is that the harmful cardiovascular effect of E4
relies on a functional interaction with LDLR. In mice, the introduction of human LDLR
results in apoE isoform-dependent differences in diet-induced atherosclerotic plaque
development (Malloy et al., 2004). In addition, the development of atherosclerosis is
accelerated in mice when human LDLR and E4 were combined in the background of
diabetes (Johnson et al., 2013). It has been proposed that these harmful effects might
originate from a reduction in the available pool of functional E4 due to “trapping” by the
LDLR (Altenburg et al., 2008, Malloy et al., 2004), but regardless of the mechanism, the
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interaction between LDLR and E4 appears to be an important disease modifying mechanism
in the setting of CVD.
While apoE has been the subject of countless studies over the past few decades, the study of
its primary receptor in the periphery, the LDLR, has been relatively understudied in the
brain. Still, several important genetic studies have implicated the LDLR – and the apoE-
LDLR interaction – as a disease modifying mechanism in AD. Gopalraj et al. (2005) showed
that a specific LDLR haplotype was associated with reduced AD risk, while Zou et al.
(2008) demonstrated that a SNP in LDLR exon 12 was associated with increased AD risk in
men. Furthermore, studies by Retz et al. (2001) and Cheng et al. (2005) demonstrated an
increase in AD risk when polymorphisms in LDLR exon 8 and exon 13 were present in
conjunction with an ε4 allele. These studies imply that a functional interaction between
apoE and LDLR may modify AD risk in an apoE isoform-dependent manner. The apoE-
LDLR interaction may play an indirect role in the context of AD, such as through regulation
of vascular function. Vascular brain injury may predict cognitive outcome better than
amyloid β deposition (Marchant et al., 2013). In addition, several vascular risk factors,
including apoE-LDLR system, are shared by AD and CVD (Altman et al., 2010).
The apoE-LDLR interaction may also play a more direct role through the modulation of
amyloid clearance and/or deposition. Several intriguing studies have shed some light onto
the potential pathophysiological pathways by which LDLR may contribute to AD. In cell
culture, overexpression of APP led to increased expression of LDLR and altered receptor
localization (Abisambra et al., 2010). Varying results in amyloid deposition have been
shown in AD mouse models lacking the LDLR, with one study showing that amyloid
deposition was enhanced on a LDLR null background (Katsouri et al., 2011), while in
another study LDLR deficiency had no effect on brain Aβ levels (Fryer et al., 2005). On the
other hand, Kim et al. (2009) showed that LDLR over-expression reduced brain apoE levels
and reduced amyloid β aggregation, while further work from the same laboratory showed
that LDLR over-expression in the brain increased the rate of brain-to-blood clearance of
both exogenously administered and endogenous Aβ (Castellano et al., 2012). These studies,
in which LDLR over-expression increases Aβ clearance, point to upregulation of LDLR in
the brain as a potential therapeutic strategy for AD. However, whether this strategy is
beneficial in the presence of all apoE isoforms remains unclear. Our previous work in the
context of CVD suggests that lipoprotein metabolism in the periphery – and possibly in the
brain as well – may be negatively affected by this strategy in the presence of apoE4
(Altenburg et al., 2007, Malloy et al., 2004, Johnson et al., 2013).
While human apoE targeted replacement (TR) mice are an invaluable research model, the
type III Hyperlipoproteinemia (HLP) and grossly elevated plasma apoE concentrations in
TR mice (and knock-in mice) with E2 are significant confounders (Mahley et al., 1999).
This is particularly significant in the context of lipid, inflammatory and other vascular
contributions in CVD and dementia. Many researchers avoid these confounding issues by
excluding E2 mice from their studies, a regrettable situation given the important protective
role of E2 in AD. It has been suggested that the type III HLP observed in E2 mice might be
a result of sub-par binding of E2 to murine apoE receptors (Sullivan98). When murine
LDLR is replaced with human LDLR, as in this study and others (Knouff et al. 2001), this
issue is resolved as plasma lipids return to normal physiological levels, allowing for study of
the ε2 allele in a physiologically relevant context.
Body mass index, obesity, insulin, and prevalence of Metabolic Syndrome, have all been
associated with APOE genotype (Elousa et al., 2003, Oh et al., 2001, Marques-Vidal et al.,
2003, Sima et al., 2007, Volcik et al., 2006). Additionally, LDLR polymorphisms have been
associated with varying degrees of body mass and adipose tissue distribution (Mattevi et al.,
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2000), and the insulin receptor (IR) has been shown to co-associate with LDLR and affect
its function (Ramakrishnan et al., 2012). The effects of apoE isoform and LDLR family
receptors on adipose tissue mass and function have been studied in both human tissue
(Huang et al., 2011) and in mice (Arbones-Mainar et al., 2008, Arbones-Mainar et al., 2010,
Karraginades et al., 2008, Schreyer et al., 2002). In this study, we did not observe
differences in body weight or adipose tissue mass based on apoE isoform or the presence of
LDLR. However, these data do not rule out potential effects of APOE genotype on adipose
tissue function, particularly in the context of metabolic challenges such as obesity or
diabetes. In fact, several studies show that E4 exacerbates the severity of cognitive
dysfunction and risk of dementia in patients with type 2 diabetes (Dore et al., 2003, Irie et
al., 2008, Kota et al., 2012, Peila et al., 2002).
Anxiety symptoms occur in 50-75% of AD patients (Gustavson et al., 2004), is more
profound in ε4 than ε3 homozygote men with probable AD (Robertson et al., 2005), and
anxiety is inversely related to cognitive function (Porter et al., 2003), particularly in E4
homozygotes (Stonnington et al., 2011). Unlike spatial memory, anxiety-like behavior was
unaffected by LDLR in this study. Instead, anxiety was strongly determined by APOE
genotype in both the presence and absence of LDLR. In the elevated zero-maze, a test of
anxiety-like behavior, mice with E4 displayed significantly more anxiety than those with E3
or E2. These data suggest that this strong APOE genotype effect on anxiety (E4 > E3 > E2)
occurs through an LDLR-independent mechanism.
Pavlovian fear conditioning is a versatile and well-understood method of assessing
associative learning (Maren, 2001). Contextual fear conditioning is considered to involve
complex polymodal processing, and to be hippocampus and amygdala-dependent, while fear
conditioning to a modality-specific cue (e.g. a tone) is considered to be hippocampus-
independent (Debiec et al., 2004). APOE genotype has been shown to affect fear
conditioning in mice (Kornecook et al., 2010, Olsen et al., 2012). In this study, we did not
observe an effect of APOE, LDLR or an APOE × LDLR interaction for contextual fear
conditioning. Conversely, we observed a strong effect of APOE genotype on cued memory.
Similar to anxiety-like behavior in the elevated zero maze, cued fear conditioning showed an
APOE effect (E4 > E3 > E2) that was similar in the presence and absence of human LDLR.
Interestingly, both of these neuropsychological processes strongly rely on the amygdala.
Although the pattern and levels of apoE in the amygdala were similar to the other brain
regions measured, these data imply that the apoE isoforms may exert unique effects in this
particular brain region through an LDLR-independent mechanism. These data may suggest
that other brain regions may play a role in modulating these effects, or more likely that – at
least in regard to the amygdale – the apoE isoform present is more important than actual
apoE levels. Alternatively, the apoE isoforms may regulate anxiety and fear learning
through neuroendocrine pathways (Raber, 2007). Previously, APOE has been implicated in
the risk and severity of post-traumatic stress disorder (PTSD) (Freeman et al., 2005, Olsen et
al., 2012, Kim et al., 2013). As apoE is highly synthesized in the steroidogenic tissues like
the adrenal gland (Blue et al., 1983, Driscoll and Getz, 1984, Elshourbagy et al., 1985) and
in certain conditions low cortisol concentrations are associated with higher risk of PTSD
(Meewisse et al., 2007), these neuroendocrine pathways may be the critical link between
various disorders of fear and anxiety and APOE genotype.
While cued associative memory and anxiety-like behavior were influenced by APOE
genotype in an LDLR-independent manner, spatial memory was heavily influenced by
LDLR expression as well as by an APOE × LDLR interaction. To assess hippocampus-
dependent spatial learning and memory, we employed the Morris water maze (WM)
(Vorhees et al., 2006). In the water maze, the absence of LDLR resulted in major deficits in
spatial memory. This supports a previous study that showed the importance of LDLR in
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spatial memory retention (Mulder et al., 2004). Here we extend these findings to show that
this effect is independent of APOE genotype. Importantly, introducing human LDLR in the
presence of E2 or E3 completely ameliorated the spatial memory deficits observed in
LDLR−/− mice. However, in the presence of E4, introducing human LDLR only partially
ameliorated these deficits; E4 mice with human LDLR demonstrated memory retention at 24
hours, but not 72 hours, post-training. These data suggest that the pathways that underlie
spatial memory - at least in regards to specific cognitive processes tested by the water maze
– require functional interaction between apoE and the LDLR. Furthermore, the interaction
between E4 and LDLR resulted in deficiencies that were not present in E2 and E3,
specifically in the context of long term memory retention (72 hours). This may be due to an
inability of the LDLR to rescue the impairments in long-term spatial memory by interacting
with E4 as it is able to do with E2 and E3. Conversely, these memory deficits may arise
through a biological mechanism that is unique to the E4-LDLR interaction. Perhaps related,
studies show that, compared to E3 mice, E4 mice have lower baseline long term potentiation
(LTP) (Trommer et al., 2004), increased LTP inhibition by Amyloid β42 (Trommer et al.,
2005), and suppression of LTP enhancement by Reelin-induction (Chen et al., 2010).
Neurons require substantial amounts of cholesterol to maintain their prolific dendritic
extensions (Yu et al., 2010), and astrocytes provide neurons with exogenous cholesterol in
the form of apoE-containing high density lipoprotein (HDL)-like particles (Boyles et al.,
1985, Boyles et al., 1989, Yu et al., 2010). The trafficking of these HDL-like particles in the
brain is likely affected by interaction of apoE with the LDLR, as it is in the periphery. To
examine whether variability in this interaction based on apoE isoform could lead to
differences in brain cholesterol concentrations, we measured cholesterol in the cortex and
hippocampus of human apoE mice with human LDLR. Neither cortical nor hippocampal
cholesterol levels o were significantly affected by APOE genotype, although there was a
trend towards lower cortical cholesterol in human LDLR mice with E4. This may suggest
that cortical cholesterol is more sensitive to apoE-LDLR mediated processes, or
hippocampal cholesterol levels may be more tightly controlled and/or managed by additional
regulatory mechanisms. However, brain cholesterol concentrations did not correlate with
any of the behavioral outcomes measured in this study.
Conflicting results concerning the role of apoE in learning and memory have been
demonstrated in apoE deficient mice. Some studies show no significant cognitive
impairments compared to either wild type or human apoE3 expressing mice (Raber et al.,
1998, Grootendorst et al., 2005, Hartman et al., 2001, van Meer et al., 2007), while others
show severe learning and memory deficits (Gordon et al., 1995, Oitzl et al., 1997, Veinbergs
et al., 1999). On the other hand, numerous studies have examined how the apoE isoforms
differentially impact the expression and function of apoE in humans and in mice (Betrand et
al., 1995, Beffert et al., 1999, Fryer et al., 2005, Fukomoto et al., 2003, Glockner et al.,
2002, Poirer et al., 2005, Ramaswamy et al., 2005, Riddell et al., 2008, Sullivan et al.,
2004). Still, it remains unclear exactly how apoE levels are altered during normal and
pathological aging, and if alterations in concentrations of brain apoE could affect pathways
of learning and memory that rely on apoE-mediated lipid trafficking or signaling (Yu et al.,
2010). Interestingly, apoE levels in E2 mice with human LDLR did not differ in any brain
region from apoE levels in any of the LDLR−/− mice. This may reflect an inability of the
LDLR to effectively regulate E2 levels in the brain, or a preference for other receptors that
play critical roles in the brain such as LRP or VLDLR. In this regard, the brain may differ
from the periphery, where the presence of human LDLR lowers plasma apoE in E2 mice to
levels 5-fold lower than LDLR−/− mice or E2 mice with endogenous mouse LDLR.
Conversely, apoE levels in E4 mice with human LDLR were significantly lower than those
of all LDLR−/− mice in the four brain regions analyzed. It has been suggested that low levels
of brain apoE exhibited by E4-carrying patients may directly contribute to the progression of
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memory loss (Riddell et al., 2008). In this study, we limited our analyses of brain apoE to
the insoluble (detergent-soluble) fraction as this preparation more accurately reflects the
levels of lipidated apoE. The lipidation status of apoE directly affects its structure and
function (Hauser et al., 2011), including its interaction with amyloid β (Fan et al., 2009,
LaDu et al., 1994, Tokuda et al., 2000). In fact, increasing the levels and lipidation of apoE
is a therapeutic mechanism attributed to the class of peroxisome proliferator-activated
receptor-γ, retinoid × receptor, and liver × receptor agonists that have shown recent promise
(Cao et al., 2007, Cramer et al., 2012, Lefterov et al., 2007, Terwel et al., 2011). Seemingly
in conflict, several studies have shown that the opposite approach of lowering brain apoE
levels may also be beneficial. Kim et al. (2011) demonstrated that lower brain apoE levels in
hemizygous human apoE mice were associated with decreased amyloid deposition.
Similarly, reducing apoE levels using Cre-mediated gene excision resulted in lower brain Aβ
levels (Bien-Ly et al., 2012). Furthermore, over-expression of LDLR – while increasing
clearance of Aβ – results in decreased brain apoE concentrations (Kim et al., 2009),
although this clearance may occur through an apoE-independent pathway (Basak et al.,
2012). Along these lines, others have suggested that increasing levels of brain apoE may be
harmful rather than beneficial in E4+ patients, due to toxic effects of the apoE4 protein itself
(Mahley et al., 2006). Perhaps another important distinction in regards to Aβ clearance is
where the apoE is located, i.e. the synapse. Tai et al. (2013) recently showed that in soluble
preparations of human synaptosomes, levels of apoE/Aβ complex were lower in AD patients
compared to controls, as well as lower in E4+ compared to E4- patients with AD. It is
unknown whether the LDLR affects apoE levels and apoE-mediated Aβ clearance at the
synapse, and further studies examining these mechanisms are warranted.
We observed a strong positive correlation between hippocampus apoE levels and
performance in the water maze. Importantly, this correlation was only observed in mice with
human LDLR. Taken together, these data suggest that: 1) LDLR regulates hippocampus
apoE levels in an isoform dependent manner, and 2) in regards to the retention of long term
spatial memory, total apoE levels may be more important than the specific isoform present.
However, due to the correlative nature of this study, the possibility remains that the isoform
of apoE present, rather than the overall level, is the key determinant of spatial memory
retention. To our knowledge, this is the first study to demonstrate an association between
hippocampus human apoE levels and cognitive performance in a test of long term spatial
memory.
In this study, we focused our analyses on hemizygous human LDLR (h/−) mice. Expression
of human LDLR in these mice is limited to a range of 16-205%, with a mean of 99%,
compared to murine LDLR in wild-type mice. It should also be noted that this study only
involved female mice, and that apoE isoform specific sex differences in behavior have been
previously shown (Raber et al., 1998, Raber et al., 2000). Regardless, a benefit of this model
is that future studies can examine effects of hyper-physiological increases in human LDLR
expression using homozygous human LDLR mice (h/h). Such studies would provide
valuable insight into the potential effects of various therapies aimed at increasing LDLR
expression – such as lowering LDL cholesterol in individuals at risk for CVD or increasing
Aβ clearance in AD patients. Of particular interest is the class of cholesterol lowering drugs
designed to inhibit PCSK9, an enzyme which enhances the degradation of the LDLR. Given
the harmful effects of increasing LDLR expression in the presence of apoE4 in a mouse
model of CVD (Altenburg et al., 2007, Johnson et al., 2013, Malloy et al., 2004), as well as
the E4-associated effects on spatial memory observed in this study, additional caution may
be needed when considering E4+ patients.
In summary, both anxiety-like behavior and cued associative memory are strongly
influenced by APOE genotype, but these processes appear to occur via an LDLR-
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independent mechanism. Conversely, plasma and brain apoE levels, cortical cholesterol, and
spatial memory are all regulated by isoform specific interactions between apoE and LDLR.
Interestingly, both the lack of LDLR and the specific interaction between E4 and the LDLR
were associated with impairments in the retention of long term spatial memory. Finally,
levels of hippocampus apoE correlate with long term spatial memory retention in mice with
human LDLR. Future studies are warranted to address the precise biological mechanisms by
which the apoE-LDLR interaction regulates brain apoE levels in an isoform dependent
manner, how varying apoE levels affect spatial memory, as well as examine the potential
apoE isoform-specific results of increasing LDLR expression as a therapeutic strategy.
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• ApoE isoform-dependent interactions with hLDLR affect plasma and brain
apoE levels
• LDLR deficient mice show apoE isoform-independent impairment in spatial
memory
• hLDLR mice with E4 have less long-term spatial memory than those with E2
and E3
• In hLDLR mice, hippocampal apoE levels positively correlate with spatial
memory
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Niether LDLR nor APOE genotype affect recognition memory in the novel object
recognition test. On Day 1, mice are exposed to two identical (“Familiar”) objects for 15
minutes. On Day 2, one of the “Familiar” objects is replaced with a unique “Novel” object
of identical dimensions. Exploration of the objects on Day 2 was video tracked and analyzed
as percent time spent examining each object. n = 6-10 per group. (6,8,8,10,6,8). * p < 0.05,
** p < 0.01
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APOE genotype affects anxiety like behavior in the elevated zero maze independent of
LDLR. The circular, elevated zero maze consists of two separate dark, walled-in “Closed”
sections and two bright, exposed “Open” sections. Mice were placed into the center of one
“Closed” section and given 15 minutes to explore. A) Number of full-body entries made into
the “Open” section from the “Closed” portion of the maze. B) Percent time spent in the
anxiety provoking “Open” section of the maze. * p < 0.05, ** p < 0.01, a p = 0.053, b p =
0.06, c p = 0.08, d p = 0.09. n = 7-10 mice per group.
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Contextual fear conditioning is unaffected by LDLR and APOE. Cued fear conditioning
responses are determined by APOE genotype independent of the LDLR. A) Experimental
design. B) Response to conditioned stimulus. The activity of the mice during the two second
0.35 mA footshock. C-D) Fear Conditioning Training. Time spent freezing (cessation of
movement with the exception of respiration) was analyzed by video software during the
training session. E) Contextual Fear Conditioning. Twenty four hours following training,
mice were exposed to an identical chamber and scent for 10 minutes and time freezing was
analyzed. F-G) Cued Fear Conditioning. Immediately following re-exposure to the context,
mice were placed in a novel environment (unique chamber, floor texture and scent) and re-
exposed to five subsequent cues (tone). n = 6-11 mice per group.
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LDLR deficiency results in severe spatial memory impairment, regardless of APOE
genotype. Mice with human LDLR and apoE4, but not apoE2 or apoE3, show impaired long
term spatial memory. A-B) Latency to platform was analyzed during the “Visible” (left
curve) and “Hidden” (right curve) trials to generate learning curves in mice lacking the
LDLR (A), and in mice with human LDLR (B). Timing of the probe trials are marked with
arrows. C-D) Probe trial, 24 hours. Time spent in each quadrant during a 60 second probe
trial, conducted 18 hours following the fourth “Hidden” training session. E-F) Probe trial, 72
hours. Time spent in each quadrant during a 60 second probe trial, conducted 72 hours
following the sixth “Hidden” training session. G-H) Representative swim pattern of E2, E3
and E4 mice with no LDLR (G) or human LDLR (H) during the 24 hour (top row) and 72
hour (bottom row) probe trials. Representative tracings were chosen based on the median
value for time spent in target quadrant for each group. * p < 0.05, ** p < 0.01, n = 7-10 per
group.
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Cortex and hippocampus cholesterol concentrations in mice with human LDLR. Cholesterol
concentrations were measured by GC/MS in the cortex and hippocampus of human LDLR
mice. n = 6-10 mice per group.
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Human LDLR expression is similar in E2, E3 and E4 mice. Plasma and brain apoE levels are
modulated by both LDLR, APOE and an APOE*LDLR interaction. A) LDLR gene
expression. mRNA was purified from mouse brain (cortex) and real time PCR performed. n
= 6-8 per group. Values are normalized to Gapdh gene expression and expressed as a
percent of average LDLR expression in wild type mice (n = 7). B) Plasma apoE (Western
blot). Plasma was collected following a four hour fast and apoE was measured by western
blot in 1 μl of plasma (0.1 μl for LDLR−/− samples). Band intensities were calculated using
Image J software. C) Plasma apoE (ELISA) in human LDLR mice. Plasma was diluted
3000-fold in PBS-T and apoE levels were measured using a sandwich ELISA. Samples were
run in triplicate and normalized to a standard curve generated using recombinant human
apoE. D) Representative blots of apoE in the cortex and hippocampus. E-H) Regional brain
apoE. ApoE in the cortex (E), amygdala (F), hippocampus (G) and cerebellum (H) was
measured by western blot. Band intensities were calculated using Image J software and
expressed relative to β-actin.
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Hippocampal ApoE correlates with spatial memory retention in mice with human LDLR. A-
B) Correlation between hippocampal apoE levels and long term (72 hours) spatial memory
retention. ApoE levels in the hippocampus positively correlate with the percent time spent in
the target quadrant in mice with human LDLR (B), but not in LDLR−/− mice (A). n = 6-12
mice per group.
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Table 1
Tissue Weights and Fasting Plasma Total Cholesterol in human ApoE mice with or without human LDLR
Genotype
Tissue Weights Plasma





E2 23.94 ± 1.74 (8) 1.108 ± 0.129 (7) 2.037 ± 0.020 (7) 0.453 ± 0.020 (8)
590.4 ± 194.7 (12)
*
E3 25.17 ± 3.58 (6) 1.200 ± 0.239 (6) 2.277 ± 0.048 (6) 0.483 ± 0.048 (6) 446.5 ± 121.8 (18)
E4 23.47 ± 3.88 (6) 1.159 ± 0.324 (6) 2.567 ± 0.049 (6) 0.474 ± 0.049 (6) 371.5 ± 84.8 (12)
Human LDLR
E2 23.68 ± 2.34 (9) 1.156 ± 0.145 (9) 2.193 ± 0.048 (9) 0.484 ± 0.048 (9)
68.7 ± 16.1 (17)
*
E3 25.35 ± 4.40 (6) 1.194 ± 0.272 (6) 2.222 ± 0.014 (6) 0.466 ± 0.014 (6) 41.4 ± 16.2 (14)
E4 23.97 ± 2.52 (6) 1.121 ± 0.174 (6) 2.617 ± 0.031 (6) 0.480 ± 0.031 (6)
63.2 ± 18.7 (18)
^
Data expressed as mean ± SEM (n).
1
Total adipose tissue weight (“Adipose”) is a combination of visceral (gonadal and retroperitoneal fat pads) and subcutaneous (right and left
posterior) fat pads.
2
For brain weight, the olfactory bulbs and brainstem were removed prior to weighing.
*
p <0.05 compared to E3 and E4.
^
p<0.05 compared to E3
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Table 2
Motor Function of human ApoE mice with or without human LDLR
Genotype
Motor Function







E2 4.67 ± 1.01 (7) 20.52 ± 1.54 (7) 15.06 ± 3.61 (7)
E3 4.42 ± 1.80 (8) 19.42 ± 3.54 (8) 16.53 ± 2.51 (8)
E4 4.80 ± 0.95 (7) 19.46 ± 6.77 (7) 15.96 ± 3.19 (7)
Human LDLR
E2 5.17 ± 1.18 (10) 21.58 ± 3.61 (10) 16.42 ± 1.78 (10)
E3 4.63 ± 1.49 (7) 19.17 ± 3.65 (7) 16.90 ± 2.45 (7)
E4 4.58 ± 0.82 (7) 22.58 ± 4.04 (7) 16.00 ± 1.32 (7)
Data expressed as mean ± SEM (n).
1
Open Field Velocity is the mean velocity (cm/s) over the course of two 10 minute exposures to the open field arena.
2
Rotarod rotations per minute (RPM) is the mean of the maximum speed achieved during each of five trials.
3
Swim speed is the mean swimming velocity (cm/s) over the course of eight trials during the visible water maze session.
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